Cargando…
Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children
BACKGROUND: Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tol...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318246/ https://www.ncbi.nlm.nih.gov/pubmed/25626448 http://dx.doi.org/10.1186/s12936-014-0521-2 |
_version_ | 1782355828435582976 |
---|---|
author | Nji, Akindeh M Ali, Innocent M Moyeh, Marcel N Ngongang, Eric-Oliver Ekollo, Aristide M Chedjou, Jean-Paul Ndikum, Valentine N Evehe, Marie S Froeschl, Guenter Heumann, Christian Mansmann, Ulrich Ogundahunsi, Olumide Mbacham, Wilfred F |
author_facet | Nji, Akindeh M Ali, Innocent M Moyeh, Marcel N Ngongang, Eric-Oliver Ekollo, Aristide M Chedjou, Jean-Paul Ndikum, Valentine N Evehe, Marie S Froeschl, Guenter Heumann, Christian Mansmann, Ulrich Ogundahunsi, Olumide Mbacham, Wilfred F |
author_sort | Nji, Akindeh M |
collection | PubMed |
description | BACKGROUND: Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP) among children aged less than ten years in two malaria-endemic ecological regions of Cameroon. METHODS: A three-arm, randomized, controlled, non-inferiority trial was conducted among children of either gender aged six months (>5 kg) to ten years (n = 720) with acute uncomplicated Plasmodium falciparum infection. Parents/guardians of children provided consent prior to randomization to receive ASAQ, DHAP or AL in the ratio of 2:2:1, respectively. Treatment outcome was assessed based on standard WHO 2003 classification after 42 days of follow-up. The primary outcome was PCR-corrected day-42 cure rates. The non-inferiority, one-sided, lower limit asymptotic 97.5% confidence interval (CI) on the difference in PCR-corrected cure rates of ASAQ and DHAP when compared to AL was accepted if the lower limit of the CI was greater than −10%. Secondary outcomes were parasite and fever clearances and day 7 haemoglobin changes. RESULTS: PCR-corrected PP cure rates of 96.7, 98.1 and 96.3, respectively, for AL, ASAQ and DHAP was observed. The lower bound of the one-sided 97.5% CI calculated around the difference between day-42 cure rate point estimates in AL and ASAQ groups, AL and DHAP groups were, −6% and −4% respectively. There were no statistical significant differences in parasite or fever clearance times between treatments, although fever clearance pattern was different between ASAQ and DHAP. No statistical significant differences were observed in the occurrence of adverse events among treatment groups. CONCLUSION: ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of uncomplicated P. falciparum malaria in Cameroonian children. TRIAL REGISTRATION: NCT01845701 |
format | Online Article Text |
id | pubmed-4318246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43182462015-02-06 Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children Nji, Akindeh M Ali, Innocent M Moyeh, Marcel N Ngongang, Eric-Oliver Ekollo, Aristide M Chedjou, Jean-Paul Ndikum, Valentine N Evehe, Marie S Froeschl, Guenter Heumann, Christian Mansmann, Ulrich Ogundahunsi, Olumide Mbacham, Wilfred F Malar J Research BACKGROUND: Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP) among children aged less than ten years in two malaria-endemic ecological regions of Cameroon. METHODS: A three-arm, randomized, controlled, non-inferiority trial was conducted among children of either gender aged six months (>5 kg) to ten years (n = 720) with acute uncomplicated Plasmodium falciparum infection. Parents/guardians of children provided consent prior to randomization to receive ASAQ, DHAP or AL in the ratio of 2:2:1, respectively. Treatment outcome was assessed based on standard WHO 2003 classification after 42 days of follow-up. The primary outcome was PCR-corrected day-42 cure rates. The non-inferiority, one-sided, lower limit asymptotic 97.5% confidence interval (CI) on the difference in PCR-corrected cure rates of ASAQ and DHAP when compared to AL was accepted if the lower limit of the CI was greater than −10%. Secondary outcomes were parasite and fever clearances and day 7 haemoglobin changes. RESULTS: PCR-corrected PP cure rates of 96.7, 98.1 and 96.3, respectively, for AL, ASAQ and DHAP was observed. The lower bound of the one-sided 97.5% CI calculated around the difference between day-42 cure rate point estimates in AL and ASAQ groups, AL and DHAP groups were, −6% and −4% respectively. There were no statistical significant differences in parasite or fever clearance times between treatments, although fever clearance pattern was different between ASAQ and DHAP. No statistical significant differences were observed in the occurrence of adverse events among treatment groups. CONCLUSION: ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of uncomplicated P. falciparum malaria in Cameroonian children. TRIAL REGISTRATION: NCT01845701 BioMed Central 2015-01-28 /pmc/articles/PMC4318246/ /pubmed/25626448 http://dx.doi.org/10.1186/s12936-014-0521-2 Text en © Nji et al.; licensee Biomed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Nji, Akindeh M Ali, Innocent M Moyeh, Marcel N Ngongang, Eric-Oliver Ekollo, Aristide M Chedjou, Jean-Paul Ndikum, Valentine N Evehe, Marie S Froeschl, Guenter Heumann, Christian Mansmann, Ulrich Ogundahunsi, Olumide Mbacham, Wilfred F Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children |
title | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children |
title_full | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children |
title_fullStr | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children |
title_full_unstemmed | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children |
title_short | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children |
title_sort | randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated plasmodium falciparum malaria in cameroonian children |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318246/ https://www.ncbi.nlm.nih.gov/pubmed/25626448 http://dx.doi.org/10.1186/s12936-014-0521-2 |
work_keys_str_mv | AT njiakindehm randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT aliinnocentm randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT moyehmarceln randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT ngongangericoliver randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT ekolloaristidem randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT chedjoujeanpaul randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT ndikumvalentinen randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT evehemaries randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT froeschlguenter randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT heumannchristian randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT mansmannulrich randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT ogundahunsiolumide randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren AT mbachamwilfredf randomizednoninferiorityandsafetytrialofdihydroartemisinpiperaquineandartesunateamodiaquineversusartemetherlumefantrineinthetreatmentofuncomplicatedplasmodiumfalciparummalariaincameroonianchildren |